The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is responsible of variable clinical manifestations, ranging from no symptoms to severe pneumonia with acute respiratory distress syndrome, septic shock, and multi-organ failure resulting in death. To date no specific antiviral drug have been approved for COVID-19, so the treatment of the disease is mainly focused on symptomatic treatment and supportive care. Moreover, there are no treatments of proven efficacy to reduce the progression of the disease from mild/moderate to severe/critical. An activation of the coagulation cascade leading to severe hypercoagulability has been detected in these patients, therefore early anticoagulation may reduce coagulopathy, microthrombus formation, and the risk of organ damages. The role of heparin in COVID-19 is supported by a lot of studies describing its pleiotropic activity but it must be proven in clinical trials. Several protocols have been designed to assess the risk-benefit profile of heparin (low-molecularweight or unfractionated heparin) in hospitalized subjects. Although prophylactic doses may be adequate in most patients, it is important to wait the results of clinical trials in order to define the appropriate effective dose able to improve disease outcome.

SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19

“…Another remarkable candidate for the treatment of COVID-19 is LMWH, with the aim to improve the coagulation dysfunction of COVID-19 [ 63 , 64 ]. Really, during the course of SARS-CoV-2 infection, an increased incidence of acute pulmonary embolism episodes was detected.…”

Why Does COVID-19 Affect Patients with Spinal Cord Injury Milder? A Case-Control Study: Results from Two Observational Cohorts

“…There are several studies that propose heparin treatment for COVID-19 patients [ 44 , 45 ]. Recently, it has been suggested that heparin might have therapeutic potential against SARS-CoV-2 infection as a competitive inhibitor [ 45 , 46 , 47 , 48 ]. Our study supports the used of heparin as treatment of choice in COVID-19, especially in SCI patients.…”

A review of potential suggested drugs for coronavirus disease (COVID-19) treatment

“…Heparin inhibits the activation of the fibrin stabilizing factor through a trombone, which prevents the fibrin clot formation. Anticoagulants, in particular heparin, are suggested for patients with severe COVID-19 ( Driggin et al, 2020 ; Gozzo et al, 2020 ). Since severe hypercoagulability occurs in these patients, early treatment with anticoagulation may decrease coagulopathy and reduce the risk of organ damages.…”